Regulatory crackdown and Novo Nordisk lawsuit rattle investors and reshape weight-loss drug landscape
Shares of Hims & Hers Health (HIMS) tumbled as much as 27% early Monday after the Food and Drug Administration signaled it would take “decisive steps” to crack down on the sale and marketing of compounded GLP-1 weight-loss drugs. The selloff deepened investor concerns about the sustainability of a key growth driver for the telehealth company, which has offered lower-cost, compounded alternatives to popular branded medications.
In a statement released Friday, the FDA said it intends to restrict the use of GLP-1 active pharmaceutical ingredients in non-FDA-approved compounded drugs that are being mass-marketed as substitutes for approved therapies. The agency specifically called out companies that promote compounded products in ways that blur the line with branded drugs, emphasizing that such medications cannot be marketed as generics, claimed to be the same as FDA-approved drugs, or advertised as clinically proven.
The regulatory pressure intensified further on Monday when Novo Nordisk, the maker of Ozempic, filed a lawsuit seeking to block Hims & Hers from selling compounded versions of its GLP-1 medications. The legal action underscores growing pushback from branded drugmakers, who argue that compounded alternatives undermine intellectual property protections and patient safety standards.
Hims & Hers has built significant demand by offering compounded GLP-1 treatments at prices well below branded options like Ozempic from Novo Nordisk and Mounjaro from Eli Lilly. While these compounded drugs contain the same active ingredient, they are not FDA-approved and are subject to stricter limitations on advertising and distribution.
The market reaction was swift and severe. With Monday’s decline, Hims & Hers shares are down roughly 50% year to date, a dramatic reversal from their February 2025 peak near $68. Investors now face a pivotal question: whether the company can pivot growth away from compounded GLP-1s and toward its broader telehealth platform, or if heightened regulatory scrutiny will materially constrain its business model going forward.
You might like this article:Stellantis Takes $26 Billion EV Write-Down as Electrification Strategy Resets
